Nanotechnology-based approaches in anticancer research

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4391-4408

  Jabir, Nasimudeen R ^a   Tabrez, Shams ^a   Ashraf, Ghulam Md ^a   Shakil, Shazi ^a   Damanhouri, Ghazi A ^a   Kamal, Mohammad A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer; Diagnosis; Drug delivery; Nanoparticle; Nanotechnology; Treatment

Indexed keywords

APTAMER; CARBON NANOTUBE; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DENDRIMER; DEXAMETHASONE; DOXORUBICIN; ENZYME RESPONSIVE NANOPARTICLE; EPIRUBICIN; GOLD NANOPARTICLE; HYDROLASE; LIPOSOMAL NANOPARTICLE; MAGNETIC NANOPARTICLE; MAGNETIC NANOVECTOR; MULTIFUNCTIONAL NANOMATERIAL; NANODIAMOND; NANOMATERIAL; NANOPARTICLE; NANOWIRE; PACLITAXEL; POLYMERIC NANOPARTICLE; PREDNISONE; QUANTUM DOT; RAPAMYCIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER DIAGNOSIS; CANCER NANOTECHNOLOGY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RESISTANCE; CELL LABELING; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TARGETING; GLIOMA; HUMAN; HYPERTHERMIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MULTIDRUG RESISTANCE; NANODEVICE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE THERAPY; REVIEW; THERMAL ABLATION; TUMOR ABLATION; TUMOR CELL; TUMOR MICROENVIRONMENT; VIRUS LIKE AGENT;

EID: 84870333528     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33838     Document Type: Review

References (220)

1. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7(1):21-33.
2. Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine. 2011;6:2963-2979.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
4. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society, 2011.
5. Choi YE, Kwak JW, Park JW. Nanotechnology for early cancer detection. Sensors. 2010;10(1):428-455.
6. Cai W, Gao T, Hong H, Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl. 2008;1:11.
7. Jean-Mary F. Spectroscopic and Microscopic Studies of Aggregated Molecules Coated onto Nanomaterials. Ann Arbor: ProQuest; 2006.
8. Elsersawi A. World of Nanobioengineering: Potential Big Ideas for the Future. Bloomington: AuthorHouse; 2010.
9. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6(3):307-318.
10. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3(1):20-31.
11. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 2003;63(23):8122-8125.
12. Nam JM, Stoeva SI, Mirkin CA. Bio-bar-code-based DNA detection with PCR-like sensitivity. J Am Chem Soc. 2004;126(19):5932-5933.
13. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
14. Neuwelt EA, Várallyay P, Bagó AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol. 2004;30(5):456-471.
15. Jamieson T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian AM. Biological applications of quantum dots. Biomaterials. 2007;28(31):4717-4732.
16. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008;49 Suppl 2:113S-128S.
17. Sikora K. The impact of future technology on cancer care. Clin Med. 2002;2(6):560-568.
18. Singh OP, Nehru RM. Nanotechnology and cancer treatment. Asian J Exp Sci. 2008;22(2):6.
19. Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 2011;14(1):67-77.
20. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5(8):1909-1917.
21. Ranganathan R, Madanmohan S, Kesavan A, etal. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine. 2012;7:1043-1060.
22. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316.
23. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005;172(12):1487-1490.
24. Ghanbari H, de Mel A, Seifalian AM. Cardiovascular application of polyhedral oligomeric silsesquioxane nanomaterials: a glimpse into prospective horizons. Int J Nanomedicine. 2011;6:775-786.
25. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57-64.
26. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615-1626.
27. Hahn MA, Singh AK, Sharma P, Brown SC, Moudgil BM. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Anal Bioanal Chem. 2011;399(1):3-27.
28. Naga AP, Siddiqui A. Nanomedical platform for drug delivery. J Nanomed Nanotechnol. 2011;2:122.
29. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649-1659.
30. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2(1):3-44.
31. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond). 2010; 5(4):597-615.
32. Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther. 2006;8(1):39-45.
33. Alexis F, Basto P, Levy-Nissenbaum E, etal. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. Chem Med Chem. 2008;3(12):1839-1843.
34. Puri A, Kramer-Marek G, Campbell-Massa R, etal. HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res. 2008;18(4):293-307.
35. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 2002;54(2):169-190.
36. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009;6(4):1041-1051.
37. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99(3):392-397.
38. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
39. Pauwels EKJ, Kairemo K, Erba P, Bergstrom K. Nanoparticles in cancer. Curr Radiopharm. 2010;1(1):30-36.
40. Zhang C, Zhao L, Dong Y, Zhang X, Lin J, Chen Z. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm. 2010;76(1):10-16.
41. Canal F, Vicent MJ, Pasut G, Schiavon O. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates. J Control Release. 2010;146(3):388-399.
42. Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm. 2010;398(1-2):190-203.
43. Ma Y, Nolte RJ, Cornelissen JJ. Virus-based nanocarriers for drug delivery. Adv Drug Deliv Rev. 2012;64(9):811-825.
44. Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer. 2005;12 Suppl 1:S189-S199.
45. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136-151.
46. Stylianopoulos T, Wong C, Bawendi MG, Jain RK, Fukumura D. Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol. 2012;508:109-130.
47. Petrelli F, Borgonovo K, Barni S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother. 2010;11(8):1413-1432.
48. Gindy ME, Prud'homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv. 2009;6(8):865-878.
49. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm. 2009;366(1-2):201-210.
50. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188(6):759-768.
51. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16-16.
52. Peng XH, Qian X, Mao H, etal. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311-321.
53. MacEwan SR, Callahan DJ, Chilkoti A. Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond). 2010;5(5):793-806.
54. Jin C, Bai L, Wu H, Liu J, Guo G, Chen J. Paclitaxel-loaded poly(D, L-lactide-co-glycolide) nanoparticles for radiotherapy in hypoxic human tumor cells in vitro. Cancer Biol Ther. 2008;7(6):911-916.
55. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131-135.
56. Choi CHJ, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010;107(3):1235-1240.
57. Kang KW, Chun MK, Kim O, etal. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine. 2010;6(2):210-213.
58. Chen AM, Zhang M, Wei D, etal. Co-delivery of doxorubicin and Bcl-2siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009;5(23):2673-2677.
59. Song XR, Cai Z, Zheng Y, etal. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci. 2009;37(3-4):300-305.
60. Koziara JM, Whisman TR, Tseng MT, Mumper RJ. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release. 2006;112(3):312-319.
61. Zhang Y, Tang L, Sun L, etal. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 2010;6(6):2045-2052.
62. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99-105.
63. Zhao D, Zhao X, Zu Y, etal. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010;5:669-677.
64. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154(2):123-140.
65. Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicol Pathol. 2008;36(1):21-29.
66. Johnston MJW, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta. 2007;1768(5):1121-1127.
67. Fenske DB, MacLachlan I, Cullis PR. Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther. 2001;3(2):153-158.
68. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5(1):25-44.
69. Semple SC, Leone R, Wang J, etal. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci. 2005;94(5):1024-1038.
70. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005;280(20):20059-20068.
71. Strijkers GJ, Kluza E, Van Tilborg GAF, etal. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis. 2010;13(2):161-173.
72. Cheng AL, Hsu CH, Lin JK, etal. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-2900.
73. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol. 2008;32(5):1119-1123.
74. Fenske DB, Wong KF, Maurer E, etal. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta. 1998;1414(1-2):188-204.
75. Johnston MJW, Semple SC, Klimuk SK, etal. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta. 2006;1758(1):55-64.
76. Rodriguez MA, Dang NH, Fayad L, etal. Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): follow-up results of a phase II study. J Clin Oncol. 2004;22(14S):8080.
77. Bhirde AA, Patel V, Gavard J, etal. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano. 2009;3(2):307-316.
78. Liu Z, Chen K, Davis C, etal. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68(16):6652-6660.
79. Chakravarty P, Marches R, Zimmerman NS, etal. Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc Natl Acad Sci U S A. 2008;105(25):8697-8702.
80. Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, Kohli K. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol. 2011;63(2):141-163.
81. Sobhani Z, Dinarvand R, Atyabi F, Ghahremani M, Adeli M. Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube. Int J Nanomedicine. 2011;6:705-719.
82. Khazaei A, Rad MNS, Borazjani MK. Organic functionalization of single-walled carbon nanotubes (SWCNTs) with some chemotherapeutic agents as a potential method for drug delivery. Int J Nanomedicine. 2010;5:639-645.
83. Krueger A. New carbon materials: biological applications of functionalized nanodiamond materials. Chemistry. 2008;14(5):1382-1390.
84. Kateb B, Chiu K, Black KL, etal. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage. 2011;54 Suppl 1:S106-S124.
85. Huang H, Pierstorff E, Osawa E, Ho D. Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett. 2007;7(11):3305-3314.
86. Lam R, Chen M, Pierstorff E, Huang H, Osawa E, Ho D. Nanodiamond-embedded microfilm devices for localized chemotherapeutic elution. ACS Nano. 2008;2(10):2095-2102.
87. Liu KK, Wang CC, Cheng CL, Chao JI. Endocytic carboxylated nanodiamond for the labeling and tracking of cell division and differentiation in cancer and stem cells. Biomaterials. 2009;30(26):4249-4259.
88. Sherman MB, Guenther RH, Tama F, etal. Removal of divalent cations induces structural transitions in red clover necrotic mosaic virus, revealing a potential mechanism for RNA release. J Virol. 2006;80(21):10395-10406.
89. Kwak M, Minten IJ, Anaya DM, etal. Virus-like particles templated by DNA micelles: a general method for loading virus nanocarriers. J Am Chem Soc. 2010;132(23):7834-7835.
90. Dixit SK, Goicochea NL, Daniel MC, etal. Quantum dot encapsulation in viral capsids. Nano Lett. 2006;6(9):1993-1999.
91. Goicochea NL, De M, Rotello VM, Mukhopadhyay S, Dragnea B. Core-like particles of an enveloped animal virus can self-assemble efficiently on artificial templates. Nano Lett. 2007;7(8):2281-2290.
92. Klostergaard J, Seeney CE. Magnetic nanovectors for drug delivery. Maturitas. 2012.
93. Kale SN, Jadhav AD, Verma S, etal. Characterization of biocompatible NiCo2O4 nanoparticles for applications in hyperthermia and drug delivery. Nanomedicine. 2012;8(4):452-459.
94. Ahamed M, Akhtar MJ, Siddiqui MA, etal. Oxidative stress mediated apoptosis induced by nickel ferrite nanoparticles in cultured A549 cells. Toxicology. 2011;283(2-3):101-108.
95. Liu L, Zhang H, Meng X, Yin J, Li D, Liu C. Dinuclear metal(II) complexes of polybenzimidazole ligands as carriers for DNA delivery. Biomaterials. 2010;31(6):1380-1391.
96. Lai BB, Chen BA, Cheng J, etal. Daunorubicin-loaded magnetic nanoparticles of Fe3O4 greatly enhance the responses of multidrug-resistant K562 leukemic cells in a nude mouse xenograft model to chemotherapy. Zhongguo Shi Yan Xue Ye Xue Za Zh. 2009;17(2):345-351.
97. Andresen TL, Thompson DH, Kaasgaard T. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy. Mol Membr Biol. 2010;27(7):353-363.
98. Gupta S, Andresen H, Ghadiali JE, Stevens MM. Kinase-actuated immunoaggregation of Peptide-conjugated gold nanoparticles. Small. 2010;6(14):1509-1513.
99. de la Rica R, Aili D, Stevens MM. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev. Epub January 14, 2012.
100. Yang Y, Aw J, Chen K, etal. Enzyme-responsive multifunctional magnetic nanoparticles for tumor intracellular drug delivery and imaging. Chem Asian J. 2011;6(6):1381-1389.
101. Gupta S, Andresen H, Stevens MM. Single-step kinase inhibitor screening using a peptide-modified gold nanoparticle platform. Chem Commun (Camb). 2011;47(8):2249-2251.
102. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4:1-7.
103. Baker JR. Dendrimer-based nanoparticles for cancer therapy. Hematology Am Soc Hematol Educ Program. 2009;2009(1):708-719.
104. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev. 2005;57(15):2106-2129.
105. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev. 2009;109(1):49-87.
106. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15(5-6):171-185.
107. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans. 2007;35(Pt 1):61-67.
108. Padilla De Jesús OL, Ihre HR, Gagne L, Fréchet JMJ, Szoka FC Jr. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem. 2002;13(3):453-461.
109. Lai PS, Lou PJ, Peng CL, etal. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release. 2007;122(1):39-46.
110. Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem. 2011;105(9):1115-1122.
111. Gillies ER, Fréchet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005;10(1):35-43.
112. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs. 1999;10(8):767-776.
113. Lee CC, Gillies ER, Fox ME, etal. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci U S A. 2006;103(45):16649-16654.
114. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
115. Han G, Ghosh P, Rotello VM. Multi-functional gold nanoparticles for drug delivery. Adv Exp Med Biol. 2007;620:48-56.
116. Chen J, McLellan JM, Siekkinen A, Xiong Y, Li ZY, Xia Y. Facile synthesis of gold-silver nanocages with controllable pores on the surface. J Am Chem Soc. 2006;128(46):14776-14777.
117. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res. 2010;12(7):2313-2333.
118. Kim B, Han G, Toley BJ, Kim CK, Rotello VM, Forbes NS. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol. 2010;5(6):465-472.
119. Brown SD, Nativo P, Smith JA, etal. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010;132(13):4678-4684.
120. Khullar P, Singh V, Mahal A, etal. Bovine serum albumin bioconjugated gold nanoparticles: synthesis, hemolysis, and cytotoxicity toward cancer cell lines. J Phys Chem C. 2012;116(15):8834-8843.
121. Joshi P, Chakraborty S, Dey S, etal. Binding of chloroquine-conjugated gold nanoparticles with bovine serum albumin. J Colloid Interface Sci. 2011;355(2):402-409.
122. Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn. 2006;6(2):231-244.
123. Gao X, Dave SR. Quantum dots for cancer molecular imaging. Adv Exp Med Biol. 2007;620:57-73.
124. Yu Y, Xu L, Chen J, etal. Hydrothermal synthesis of GSH-TGA co-capped CdTe quantum dots and their application in labeling colorectal cancer cells. Colloids Surf B Biointerfaces. 2012;95:247-253.
125. Shen JM, Tang WJ, Zhang XL, Chen T, Zhang HX. A novel carboxymethyl chitosan-based folate/Fe3O4/CdTe nanoparticle for targeted drug delivery and cell imaging. Carbohydr Polym. 2012;88(1):239-249.
126. Li JM, Wang YY, Zhao MX, etal. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials. 2012;33(9):2780-2790.
127. Wang Y, Zhang Y, Du Z, Wu M, Zhang G. Detection of micrometastases in lung cancer with magnetic nanoparticles and quantum dots. Int J Nanomedicine. 2012;7:2315-2324.
128. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
129. Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm. 2012;430(1-2):238-246.
130. Shi SJ, Zhong ZR, Liu J, Zhang ZR, Sun X, Gong T. Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm Res. 2012;29(1):97-109.
131. Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomater. 2011;2011:1-10.
132. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887-913.
133. van Vlerken LE, Amiji MM. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv. 2006;3(2):205-216.
134. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
135. Hu S, Zhang Y. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int J Nanomedicine. 2010;5:1039-1048.
136. Woo HN, Chung HK, Ju EJ, etal. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int J Nanomedicine. 2012;7:2197-2208.
137. Aravind A, Jeyamohan P, Nair R, etal. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng. Epub May 21, 2012.
138. Guo J, Gao X, Su L, etal. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010-8020.
139. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356-17361.
140. Chen J, Li S, Shen Q, He H, Zhang Y. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug Dev Ind Pharm. 2011;37(11):1339-1346.
141. Cho H, Bae J, Garripelli VK, Anderson JM, Jun HW, Jo S. Redox-sensitive polymeric nanoparticles for drug delivery. Chem Commun (Camb). 2012.
142. Prajapati BG. Nanoparticles as platforms for targeted drug delivery system in cancer therapy. Internet J Nanotechnol. 2009;3(1):1-8.
143. Stern JM, Cadeddu JA. Emerging use of nanoparticles for the therapeutic ablation of urologic malignancies. Urol Oncol. 2008;26(1):93-96.
144. Milleron RS, Bratton SB. 'Heated' debates in apoptosis. Cell Mol Life Sci. 2007;64(18):2329-2333.
145. Cherukuri P, Glazer ES, Curley SA. Targeted hyperthermia using metal nanoparticles. Adv Drug Deliv Rev. 2010;62(3):339-345.
146. Ellis LM, Curley SA, Tanabe KK. Radiofrequency Ablation for Cancer: Current Indications, Techniques, and Outcomes. New York: Springer-Verlag; 2004.
147. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. J Pharm Bioallied Sci. 2010;2(4):282-289.
148. Samanta B, Yan H, Fischer NO, Shi J, Jerry DJ, Rotello VM. Protein-passivated Fe3O4 nanoparticles: low toxicity and rapid heating for thermal therapy. J Mater Chem. 2008;18(11):1204-1208.
149. Kam NWS, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc. 2005;127(36):12492-12493.
150. Gannon CJ, Cherukuri P, Yakobson BI, etal. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer. 2007;110(12):2654-2665.
151. Samia ACS, Chen X, Burda C. Semiconductor quantum dots for photodynamic therapy. J Am Chem Soc. 2003;125(51):15736-15737.
152. Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Baba Y. Quantum dots as photosensitizers? Nat Biotechnol. 2004;22(11):1360-1361.
153. Letfullin RR, Iversen CB, George TF. Modeling nanophotothermal therapy: kinetics of thermal ablation of healthy and cancerous cell organelles and gold nanoparticles. Nanomedicine. 2011;7(2):137-145.
154. Fillat C, Jose A, Bofill-DeRos X, Mato-Berciano A, Maliandi MV, Sobrevals L. Pancreatic cancer gene therapy: from molecular targets to delivery systems. Cancers. 2011;3(1):368-395.
155. Song WJ, Du JZ, Sun TM, Zhang PZ, Wang J. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small. 2010;6(2):239-246.
156. Liu J, Sonshine DA, Shervani S, Hurt RH. Controlled release of biologically active silver from nanosilver surfaces. ACS Nano. 2010;4(11):6903-6913.
157. Nunes A, Amsharov N, Guo C, etal. Hybrid polymer-grafted multiwalled carbon nanotubes for in vitro gene delivery. Small. 2010;6(20):2281-2291.
158. Ewert KK, Zidovska A, Ahmad A, etal. Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem. 2010;296:191-226.
159. Tanner P, Baumann P, Enea R, Onaca O, Palivan C, Meier W. Polymeric vesicles: from drug carriers to nanoreactors and artificial organelles. Acc Chem Res. 2011;44(10):1039-1049.
160. Kim TH, Jin H, Kim HW, Cho MH, Cho CS. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther. 2006;5(7):1723-1732.
161. Talaei F, Azizi E, Dinarvand R, Atyabi F. Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells. Int J Nanomedicine. 2011;6:1963-1975.
162. Pirollo KF, Rait A, Zhou Q, etal. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 2007;67(7):2938-2943.
163. Gopalan B, Ito I, Branch CD, Stephens C, Roth JA, Ramesh R. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat. 2004;3(6):647-657.
164. Zhang L, Gao X, Men K, etal. Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticle-mediated survivin T34A. Int J Nanomedicine. 2011;6:2419-2427.
165. Xu Z, Shen G, Xia X, etal. Comparisons of three polyethyleneimine-derived nanoparticles as a gene therapy delivery system for renal cell carcinoma. J Transl Med. 2011;9(1):46-46.
166. Chen AA, Derfus AM, Khetani SR, Bhatia SN. Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic Acids Res. 2005;33(22):e190.
167. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064-1079.
168. Cai D, Mataraza JM, Qin ZH, etal. Highly efficient molecular delivery into mammalian cells using carbon nanotube spearing. Nat Methods. 2005;2(6):449-454.
169. Elhissi AMA, Ahmed W, Hassan IU, Dhanak VR, D'Emanuele A. Carbon nanotubes in cancer therapy and drug delivery. J Drug Deliv. 2012;2012:Article ID 837327.
170. Podesta JE, Al-Jamal KT, Herrero MA, etal. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small. 2009;5(10):1176-1185.
171. Barker SL, Shortreed MR, Kopelman R. Utilization of lipophilic ionic additives in liquid polymer film optodes for selective anion activity measurements. Anal Chem. 1997;69(6):990-995.
172. Choi Y, Thomas T, Kotlyar A, Islam MT, Baker JR Jr. Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chem Biol. 2005;12(1):35-43.
173. Duncan R MN. Dendrimers: biocompatibility and potential for delivery of anticancer agents. Proc Int Symp Control Release Bioact Mater. 1996;23:105-106.
174. Varkouhi AK, Foillard S, Lammers T, etal. SiRNA delivery with functionalized carbon nanotubes. Int J Pharm. 2011;416(2):419-425.
175. Yao H, Ng SS, Huo LF, etal. Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle. Mol Cancer Ther. 2011;10(6):1082-1092.
176. Prakash S, Wei Shao M, Paul A, etal. A novel polyethyleneimine-coated adeno-associated virus-like particle formulation for efficient siRNA delivery in breast cancer therapy: preparation and in vitro analysis. Int J Nanomedicine. 2012:1575-1586.
177. Fortina P, Kricka LJ. Nanotechnology: improving clinical testing? Clin Chem. 2010;56(9):1384-1389.
178. Chi X, Huang D, Zhao Z, Zhou Z, Yin Z, Gao J. Nanoprobes for in vitro diagnostics of cancer and infectious diseases. Biomaterials. 2012;33(1):189-206.
179. Sullivan DC, Ferrari M. Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging. 2004;3(4):364-369.
180. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;4(6):435-446.
181. Pericleous P, Gazouli M, Lyberopoulou A, Rizos S, Nikiteas N, Efstathopoulos EP. Quantum dots hold promise for early cancer imaging and detection. Int J Cancer. 2012;131(3):519-528.
182. Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev. 2008;60(11):1226-1240.
183. Gao J, Chen X, Cheng Z. Near-infrared quantum dots as optical probes for tumor imaging. Curr Top Med Chem. 2010;10(12):1147-1157.
184. Frasco MF, Chaniotakis N. Semiconductor quantum dots in chemical sensors and biosensors. Sensors (Basel). 2009;9(9):7266-7286.
185. Hu M, Yan J, He Y, etal. Ultrasensitive, multiplexed detection of cancer biomarkers directly in serum by using a quantum dot-based microfluidic protein chip. ACS Nano. 2010;4(1):488-494.
186. Bailey VJ, Easwaran H, Zhang Y, etal. MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Res. 2009;19(8):1455-1461.
187. So MK, Xu C, Loening AM, Gambhir SS, Rao J. Self-illuminating quantum dot conjugates for in vivo imaging. Nat Biotechnol. 2006;24(3):339-343.
188. Xia Z, Xing Y, So MK, Koh AL, Sinclair R, Rao J. Multiplex detection of protease activity with quantum dot nanosensors prepared by intein-mediated specific bioconjugation. Anal Chem. 2008;80(22):8649-8655.
189. Jun YW, Sheikholeslami S, Hostetter DR, Tajon C, Craik CS, Alivisatos AP. Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level. Proc Natl Acad Sci U S A. 2009;106(42):17735-17740.
190. Lee SE, Lee LP. Biomolecular plasmonics for quantitative biology and nanomedicine. Curr Opin Biotechnol. 2010;21(4):489-497.
191. Osterfeld SJ, Yu H, Gaster RS, etal. Multiplex protein assays based on real-time magnetic nanotag sensing. Proc Natl Acad Sci U S A. 2008;105(52):20637-20640.
192. Hirsch LR, Jackson JB, Lee A, Halas NJ, West JL. A whole blood immunoassay using gold nanoshells. Anal Chem. 2003;75(10):2377-2381.
193. Zhao X, Tapec-Dytioco R, Tan W. Ultrasensitive DNA detection using highly fluorescent bioconjugated nanoparticles. J Am Chem Soc. 2003;125(38):11474-11475.
194. Wu X, Liu H, Liu J, etal. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol. 2003;21(1):41-46.
195. Santra S, Zhang P, Wang K, Tapec R, Tan W. Conjugation of biomolecules with luminophore-doped silica nanoparticles for photostable biomarkers. Anal Chem. 2001;73(20):4988-4993.
196. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl. 2009;48(5):872-897.
197. Yue M, Lin H, Dedrick DE, etal. A 2-D microcantilever array for multiplexed biomolecular analysis. J Microelectromech Syst. 2004;13(2):290-299.
198. Majumdar A. Bioassays based on molecular nanomechanics. Dis Markers. 2002;18(4):167-174.
199. Zheng G, Patolsky F, Cui Y, Wang WU, Lieber CM. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol. 2005;23(10):1294-1301.
200. Stern E, Vacic A, Rajan NK, etal. Label-free biomarker detection from whole blood. Nat Nanotechnol. 2010;5(2):138-142.
201. Sun YP, Fu K, Lin Y, Huang W. Functionalized carbon nanotubes: properties and applications. Acc Chem Res. 2002;35(12):1096-1104.
202. Liu Z, Tabakman S, Welsher K, Dai H. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009;2(2):85-120.
203. Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed Engl. 2008;47(38):7284-7288.
204. Mistlberger G, Koren K, Scheucher E, etal. Multifunctional magnetic optical sensor particles with tunable sizes for monitoring metabolic parameters and as a basis for nanotherapeutics. Adv Funct Mater. 2010;20(11):1842-1851.
205. Yong KT. Biophotonics and biotechnology in pancreatic cancer: cyclic RGD-peptide-conjugated type II quantum dots for in vivo imaging. Pancreatology. 2010;10(5):553-564.
206. Bünzli JC. Lanthanide luminescence for biomedical analyses and imaging. Chem Rev. 2010;110(5):2729-2755.
207. Sitharaman B, Avti. Luminescent single-walled carbon nanotube-sensitized europium nanoprobes for cellular imaging. Int J Nanomedicine. 2012:1953-1953.
208. Lewis DJ, Bruce C, Bohic S, etal. Intracellular synchrotron nanoimaging and DNA damage/genotoxicity screening of novel lanthanide-coated nanovectors. Nanomedicine (Lond). 2010;5(10):1547-1557.
209. Liu Y, Zhang N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials. 2012;33(21):5363-5375.
210. Wang X, Wang C, Cheng L, Lee ST, Liu Z. Noble metal coated single-walled carbon nanotubes for applications in surface enhanced Raman scattering imaging and photothermal therapy. J Am Chem Soc. 2012;134(17):7414-7422.
211. Cordovilla C, Swager TM. Strain release in organic photonic nanoparticles for protease sensing. J Am Chem Soc. 2012;134(16):6932-6935.
212. Ling Y, Wei K, Zou F, Zhong S. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int J Pharm. 2012;430(1-2):266-275.
213. Dong H, Lei J, Ju H, etal. Target-cell-specific delivery, imaging, and detection of intracellular MicroRNA with a multifunctional SnO2 nanoprobe. Angew Chem Int Ed Engl. 2012;51(19):4607-4612.
214. Tao L, Zhang K, Sun Y, Jin B, Zhang Z, Yang K. Anti-epithelial cell adhesion molecule monoclonal antibody conjugated fluorescent nanoparticle biosensor for sensitive detection of colon cancer cells. Biosens Bioelectron. 2012;35(1):186-192.
215. Liu K, Liu X, Zeng Q, etal. Covalently assembled NIR Nanoplatform for simultaneous fluorescence imaging and photodynamic therapy of cancer cells. ACS Nano. 2012;6(5):4054-4062.
216. Ferguson RM, Khandhar AP, Krishnan KM. Tracer design for magnetic particle imaging (invited). J Appl Phys. 2012;111(7):7B318-317B3185.
217. Puvanakrishnan P, Diagaradjane P, Kazmi SMS, Dunn AK, Krishnan S, Tunnell JW. Narrow band imaging of squamous cell carcinoma tumors using topically delivered anti-EGFR antibody conjugated gold nanorods. Lasers Surg Med. 2012;44(4):310-317.
218. El-Dakdouki MH, Zhu DC, El-Boubbou K, etal. Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. Biomacromolecules. 2012;13(4):1144-1151.
219. Cho K, Wang X, Nie S, Chen Z and Shin DM. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin Cancer Res. 2008;14:1310-1316.
220. McBain SC, Yiu HHP, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine. 2008;3(2):169-180.